Lexaria Bioscience Corp. Enters Material Transfer Agreement with Pegbio Co., Ltd. to Investigate DehydraTECH Technology for GLP-1 Industry
Kelowna, British Columbia — August 13, 2026 — Leads & Copy — Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has entered into a Material Transfer Agreement (MTA) with Pegbio Co., Ltd. to investigate Lexaria’s DehydraTECH technology with a proprietary PegBio molecule intended for the GLP-1 industry. This agreement is distinct from Lexaria’s existing MTA with another pharmaceutical company.
Under the terms of the MTA, PegBio will provide Lexaria with a proprietary GLP-1 molecule. Lexaria will then process this molecule using its patented DehydraTECH technology and evaluate its pharmacokinetic performance in animal studies.
“We welcome PegBio to our expanding group of potential future commercial partners for DehydraTECH-powered GLP-1 drugs,” said Richard Christoper, CEO of Lexaria Bioscience Corp. “PegBio has built an impressive group of GLP-1-related drug products and candidates focused on type-2 diabetes, weight loss, and MASH*. Lexaria is excited that our proprietary technology may assist in making their drugs as accessible and effective as possible.”
PegBio’s lead product is a GLP-1 molecule approved for use in China via injection in November 2025. The company also has several other molecules that have progressed from preclinical stages to Phase II trials in both China and the USA.
Lexaria was introduced to PegBio through Liberi Group, a global life sciences business development consultancy that is assisting Lexaria with its DehydraTECH partnering strategy.
Lexaria plans to provide an update following the completion of the study(ies), including any business decisions made regarding technology licensing or other ventures.
*metabolic dysfunction-associated steatohepatitis
About PegBio
PegBio is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for metabolic and related chronic diseases. Its first internally developed drug, the long-acting GLP-1 receptor agonist PB-119 (Visepegenatide Injection), received approval in China in November 2025 and has entered commercialization. PegBio is advancing a pipeline of differentiated next-generation therapies for diabetes, obesity, and other metabolic diseases, while developing an intelligent R&D and data platform that integrates artificial intelligence, computational science, and biotechnology. PegBio is listed on The Stock Exchange of Hong Kong Limited (HKG:2565).
For more information, please visit pegbio.com.
About Lexaria Bioscience Corp. & DehydraTECH™
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology designed to enhance oral delivery of various drugs by improving their entry into the bloodstream. DehydraTECH™ has demonstrated an ability to increase bio-absorption, reduce side-effects, and improve the delivery of certain drugs across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 granted patents and additional patents pending worldwide.
For more information, please visit www.lexariabioscience.com.
About Liberi Group
Liberi Group is a global business development and strategic consultancy focused on the life sciences and biotech industries. The firm collaborates with innovative biotech and pharmaceutical companies to identify, structure, and advance strategic partnerships, licensing agreements, and investor relationships across global markets. Liberi Group combines deep scientific understanding with an extensive network of industry relationships to connect promising technologies with suitable partners. This collaboration between Lexaria and PegBio is a result of Liberi Group’s ongoing efforts to support Lexaria’s DehydraTECH partnering strategy.
For more information, please visit Global Life Science Consulting.
Source: Lexaria Bioscience Corp.
Share this story:
